Adverum Biotechnologies (STU:AVU0) Total Stockholders Equity : €167.71 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Total Stockholders Equity?

Adverum Biotechnologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €167.71 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Adverum Biotechnologies's Book Value per Share for the quarter that ended in Mar. 2024 was €16.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Adverum Biotechnologies's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.41.

Adverum Biotechnologies Total Stockholders Equity Historical Data

The historical data trend for Adverum Biotechnologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Total Stockholders Equity Chart

Adverum Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

157.46

357.03

279.82

171.35

76.54

Adverum Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															147.35	121.06	96.24	76.54	167.71

Adverum Biotechnologies (STU:AVU0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Adverum Biotechnologies's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(167.705	-	0)	/	10.1433
	=	16.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Adverum Biotechnologies's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.653	+	58.872)	/	167.705
	=	0.41

Adverum Biotechnologies Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies (STU:AVU0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (STU:AVU0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ADVM:USA

Address

100 Cardinal Way, Redwood CIty, CA, USA, 94063

Website

https://www.adverum.com

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (STU:AVU0) Headlines

No Headlines